- Conditions
- Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)
- Interventions
- Burosumab
- Biological
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 7
- States / cities
- Golden, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced May 22, 2026, 12:39 AM EDT